

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

OIPE JC106
DEC 30 2002
TRADEMARK OFFICE




FIG. 2

OIP E JC106
DEC 30 2002
PATENT & TRADEMARK OFFICE




FIG. 3

CVT ABCA1 Gene Structure




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




Fig. 10




FIG. 11





FIG. 12



1 GAAATTCCTTGTGGTGGCTCCACATGCACCTTCCAGGGCCCTGCTTGGCTCTTCTATGGGTCTGTCTGAGTGTGTGATAGAAACCACTGATGTGAGTACCTGG
101 GCTTGAGCGTGGCTGGAGATCCCTGTTGACTGTAGCATGGAGGGGCTTGTCAAGCTGAATGTCTGTATGCAGGTGGTGGGAGTTCTCGGAATATGATGGAG
201 CTGGAGGTGGGAAGAGAGTAGGCTTGGGGCAGCTCTCTCATGCGACCTCATTTCTGGCCAAAACCTCAGGTCAAACCTGTGAAAGAGTCTAAATGTGAATCTG
301 CCTTCAAGGTGGCTACAAAGGTATCTTTGTCAAGGTAGGAGACCTTGTGGCCCTCACGTGCATTTCCAGGGCCCTGTGGCCCTCTTCTACGGGTCTGTG
401 CTGAGTCTTCTATGAATCTCCCTTCAGGGCAGATTCAATTTAGACTCTTCACAGTTTGACCTGAGTTTGGCCAGAATAAGGTGACATTTAGTTTGTGTTG
501 GCTTGATGAATGACTTAAATAATTTAGACATATGTTGTGTAGGCCCTGCTTCTACTCTTGGCTTTTGGCCCTCAGTGTTTTGGGTAGTTTGTGCT
601 CCCCCACAGCCAAAGGCAACAGATAAGTTGGAGGCTCTGGATGGCTACATAATTTTACACGACTGCATAATCTCTGGCTGCATTCACACAAATGTATATACA
701 AACTAAATACAAGTCTGTGTTTTATCACAGGGAGGCTGATCAATATAATGAATAATAAAGGGGCTGTGCCATATTGTTCTGTGTTTTTGTGTTGTTT
801 GTTCTTTTTTTTGTGGCCCTCTTCTCAATTTATGAAGAGAAGCAGTAAGATGTTCTCTCGGTCTCTGTAGGAGCACTTGGGGAGCTTCAGGC
901 TGGGAATCTCCAAGGCAGTAGTGCCTATCAAAAATCAAAGTCCAGGTTTGTGGGGGAAAACAAAAGCAGCCCCATTACCCAGAGGACTGTCCGCCCTTC
1001 CCTCACCCCAGCTTAGGCCTTTGAAAAGGAAACAAAAGACAAAGCAAAAATGATTGGCGTCTGTAGGAGATTACAGCCTAGAGCTCTCTCTCCCCCAATCC
1101 CTCCCTCCGGCTGAGGAAACTAAACAAAGGAAACAAAATTTGGGAAAGCAGGATTTAGAGGAAGCAAAATTCACATGGTGCCTTGGCTGCCGGGAACGTTG
1201 GACTAGAGAGTCTGGCGGCAGCCCCGAGCCCGCTCTCCCGCGCTCTTAGGCCGCGGGCCCCGGGGGGAAGGGGAACGACAGCCCGGACCCCTAA
1301 GACACCTGCTGPACCTTCCACCCCAACCCACCTCCCCCAACTCCCTAGATGTGTCTGTGGGGGTGAAAGCTCGCCCTGTTTAAAGGGGGGGGGCCCC
1401 GGCTCCACGTGCTTCTGCTGAGTGAATGAACATACATAAACAGAGGCCGGGAACGGGGCGGGAGGAGGACAGGCTTTGACCGGATAGTAACCTC
1501 TGGGCTCGGTGCAGCCGAATCTATAAAGGAACATAGTCCCGGCAAAAACCCCGTAATTGCGAGCGAGAGTGTGGGGGCGGGGACCCGACAGCCGAGCC
601 GACCTTCTCTCCGGGCTGGCGAGGGCAGGGGGGAGCTC (SEQ ID NO. 3)

→transcription start site

TATA box

☐ nuclear hormone receptor half site

☐ LXR response element

SP1 site

FIG. 13

A circular black ink stamp from the Office of Intellectual Property (OIPE). The text "OIPE" is at the top, "DEC 30 2002" is in the center, and "OFFICE OF INTELLECTUAL PROPERTY" is around the bottom edge.

1 GAATTCTTGCTGGTGGCTCCACATGCATTCAGGGCCTGCTTGGCTCTCTATGGGTCTGTCTCTAGTGTGATAGAAACCACTGATGTGAGTACCTGG
101 GCTTGAGCGTGGCCTGGAGATCCTGTTGACTGTAGCATGGAGGGGCTTGTTCAGCTGAATGTCTGTATGCAGGTGGTGGGAGTTCTTGGAAATATGATGGAG
201 CTGGAGGTGGGAAGAGAACTAGGCTTGGGCGAGCTCTCTCATGCCACCTCAATCTTGGCCAAAACCTCAGGTCAAACTGTGAAGAGTCTAAATGTGAATCTG
301 CCTTCAAGGTGGCTACAAAGGTATCTTTCTCAAGGTAGGAGACCTTGTGGCTCCACGTGCATTCAGGGCCCTGCTTGGCCCTCTTCTACCGGTCTGTC
401 CTGAGTCTTCTATGAATCTCCCTTCAGGGCAGATTCTATTTAGACTCTTTCACAGTTTGACCTTGAGCTTTTGGCCAGAAATAAGGTGACATTTAGTTTGTGTG
501 GCTTGATGAATGACTTTAAATATTTAGACATATGTTGTGTAGGCCCTGCAATTCCTACTCTTGGCTTTTGTGCCCCCTCCAGTGTTTTGGGTAGTTTTGTGCT
601 CCCCCACAGCCAAAGGCAAAACAGATAAGTTGGAGGCTCGAGTGGCTACATAATTTTACACGACTGCAATCTCTGGCTGCACTTTCACAAATGTATACA
701 AACTAAATACAAGTCTGTGTTTTTATCACAGGGAGGCTGATCAATATAATGAATAATAAAGGGGCTGGTCCCATATTGTTCTGTGTTTTTGTGTTGTTT
801 GTTCTCTTTTGTGTCCTCTCTCTCTCAATTTATGAAGAGACGAGTAAGATGTTCTCTCGGTCTCTGAGGACCTTGGGAGCTCAGGC
901 TGGGAATCTCCAAGGCAGTAGGTGGCTATCAAAATCAAAGTCCAGGTTTGTGGGGGAAACAAAAGCAGCCCCATTACCCAGAGGACTGTCCGCCCTTC
1001 CCTCACCCAGCCTAGGCCCTTTGAAGAGGAACAAAAGACAAAATGATTTGGCGTCTCTGAGGAGATTACGCTAGAGCTCTCTCTCCCCCAATCC
1101 CTCCCTCCGCTGAGGAAACTAAACAAAGGAAAAAAAATTGCGGAAGCAGGATTTAGAGGAAGCAAAATCCACTGGTGGCTTGGCTCCCGGGAACGCTG
1201 GACTAGAGATCTGGCGGCGAGCCCGAGCCCGAGCTTCCCGCGCTCTTAGGCCGCGGGCCCGGGCGGGGAAGGGGACGCAGACCGCGGACCCCTAA
1301 GACACCTGTGTACCTCCACCCACCCACCCACCTCCCCCAACTCCCTAGATGTGTGTTGGCGGCTGAACGTGCCCCGTTTAAAGGGCGGGGCCCC
1401 GGCTCCACGTGCTTCTGCTGAGTGAATGAACATACATAAACAGAGGCCGGGAACGGGGCGGGGAGGAGGAGACAGGCTTTGACCGATAGTAACCTTC
1501 TGGCGCTGGTGCAGCCGAATCTATAAAGGAACACTAGTCCCGCAAAACCCCGTAATTCGAGCGGAGAGTGAAGTGGGCGCGGGAACCGCGAGCGCGAGCC
1601 GACCTTCTCTCCGGCTGCGGAGGGCAGGGCGGGAGCTC (SEQ ID NO. 3)

TATA box

 nuclear hormone receptor half site

☐ LXR response element

~~_____~~ SPL site

FIG. 13